Cost effectiveness of renal disease screening

Area of Science:

• Nephrology
• Public Health
• Screening Programs

Background:

• Kidney diseases are a significant cause of mortality and disability.
• Current therapeutic methods offer limited ability to halt the progression of many chronic renal diseases.
• Evidence supporting the benefit of early screening for chronic kidney disease (CKD) in the general population is scarce.

Purpose of the Study:

• To evaluate the effectiveness of early screening for chronic kidney disease (CKD).
• To determine if early identification and intervention can positively influence patient prognosis.
• To assess the potential benefits versus harms of screening asymptomatic individuals for renal abnormalities.

Main Methods:

• Review of existing evidence on the impact of early screening for CKD.
• Analysis of the efficacy of current therapeutic interventions in arresting disease progression.
• Consideration of the economic and psychosocial implications of screening asymptomatic populations.

Main Results:

• The search for evidence supporting the benefit of early CKD screening has been largely unrewarding.
• Limited evidence exists to suggest that current therapies can arrest the progressive course of many chronic renal diseases.
• Screening asymptomatic individuals may lead to unnecessary economic and psychosocial burdens due to benign or transient urinary abnormalities.

Conclusions:

• Except for detecting bacteriuria in pregnant women, early identification of CKD is generally not recommended.
• The potential harms of screening, including economic and psychosocial issues, outweigh the limited proven benefits for asymptomatic individuals.
• Further research may be needed to identify specific subgroups that could benefit from early CKD screening.